Drug Development and Krüppel-like Factors

  • Ichiro Manabe
  • Ryozo Nagai


Recent advances in our understanding of the disease biology of KLFs have spurred considerable interest in their potential to serve as therapeutic targets. Results obtained with small molecules and nucleic acids (e.g., siRNA) targeting KLFs in vitro and in vivo strongly support the feasibility of therapeutic modulation of KLFs for the treatment of cancer as well as cardiovascular and metabolic diseases. Nonetheless, a better understanding of the precise mode of action of KLF in its transcription network, particularly its interaction with other transcription factors and cofactors and its posttranslational modification, would further facilitate development of KLF therapeutics. Moreover, development of improved drug delivery systems would increase the number of diseases that could be targeted by siRNA against KLFs. KLFs have also been used to induce pluripotency in induced pluripotent stem (iPS) cells, suggesting that pharmacological modulation of KLFs may be a useful approach to tailoring iPS cells and their derivatives.


HDAC Inhibitor Betulinic Acid Glycyrrhetinic Acid Nuclear Receptor Ligand Transcription Factor KLF5 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akhtar S and Benter IF (2007) Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 117:3623–3632PubMedCrossRefGoogle Scholar
  2. Atkins GB and Jain MK (2007) Role of Kruppel-Like Transcription Factors in Endothelial Biology. Circ Res 100:1686–1695PubMedCrossRefGoogle Scholar
  3. Chen X and Bieker JJ (2001) Unanticipated Repression Function Linked to Erythroid Kruppel-Like Factor. Mol Cell Biol 21:3118–3125PubMedCrossRefGoogle Scholar
  4. Chen ZY and Tseng C-C (2005) 15-Deoxy-{Delta}12,14 Prostaglandin J2 Up-Regulates Kruppel-Like Factor 4 Expression Independently of Peroxisome Proliferator-Activated Receptor {gamma} by Activating the Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Signal Transduction Pathway in HT-29 Colon Cancer Cells. Mol Pharmacol 68:1203–1213PubMedCrossRefGoogle Scholar
  5. Chintharlapalli S, Papineni S, Jutooru I et al (2007a) Structure-dependent activity of glycyrrhe-tinic acid derivatives as peroxisome proliferator-activated receptor {gamma} agonists in colon cancer cells. Mol Cancer Ther 6:1588–1598CrossRefGoogle Scholar
  6. Chintharlapalli S, Papineni S, Liu S et al (2007b) 2-Cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor {gamma} in colon and pancreatic cancer cells. Carcinogenesis 28:2337–2346CrossRefGoogle Scholar
  7. Dokmanovic M, Clarke C, Marks PA (2007) Histone Deacetylase Inhibitors: Overview and Perspectives. Mol Cancer Res 5:981–989PubMedCrossRefGoogle Scholar
  8. Emery JG, Ohlstein EH, Jaye M (2001) Therapeutic modulation of transcription factor activity. Trends Pharmacol Sci 22:233–240PubMedCrossRefGoogle Scholar
  9. Fujiu K, Manabe I, Ishihara A et al (2005) Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5. Circ Res 97:1132–1141PubMedCrossRefGoogle Scholar
  10. Ghaleb AM and Yang VW (2008) The Pathobiology of Kruppel-like Factors in Colorectal Cancer. Curr Colorectal Cancer Rep 4:59–64PubMedCrossRefGoogle Scholar
  11. Imming P, Sinning C, Meyer A (2006) Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 5:821–834PubMedCrossRefGoogle Scholar
  12. Kaczynski J, Zhang J-S, Ellenrieder V et al (2001) The Sp1-like Protein BTEB3 Inhibits Transcription via the Basic Transcription Element Box by Interacting with mSin3A and HDAC-1 Co-repressors and Competing with Sp1. J Biol Chem 276:36749–36756PubMedCrossRefGoogle Scholar
  13. Koro C, Barrett S, Nawab Qizilbash (2007) Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 16:485–492PubMedCrossRefGoogle Scholar
  14. Kremoser C, Albers M, Burris TP et al (2007) Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators. Drug Discov Today 12:860–869PubMedCrossRefGoogle Scholar
  15. Landry Y and Gies J-P (2008) Drugs and their molecular targets: an updated overview. Fundam Clin Pharmacol 22:1–18PubMedCrossRefGoogle Scholar
  16. Li D, Yea S, Li S et al (2005) Kruppel-like Factor-6 Promotes Preadipocyte Differentiation through Histone Deacetylase 3-dependent Repression of DLK1. J Biol Chem 280:26941–26952PubMedCrossRefGoogle Scholar
  17. Liu S, Zhang H, Zhu L et al (2008) Kruppel-Like Factor 4 Is a Novel Mediator of Selenium in Growth Inhibition. Mol Cancer Res 6:306–313PubMedCrossRefGoogle Scholar
  18. Matsumura T, Suzuki T, Aizawa K et al (2005) The Deacetylase HDAC1 Negatively Regulates the Cardiovascular Transcription Factor Kruppel-like Factor 5 through Direct Interaction. J Biol Chem 280:12123–12129PubMedCrossRefGoogle Scholar
  19. McConnell BB, Ghaleb AM, Nandan MO, Yang VW (2007) The diverse functions of Kruppel-like factors 4 and 5 in epithelial biology and pathobiology. Bioessays 29:549–557PubMedCrossRefGoogle Scholar
  20. Narla G, DiFeo A, Yao S et al (2005) Targeted Inhibition of the KLF6 Splice Variant, KLF6 SV1, Suppresses Prostate Cancer Cell Growth and Spread. Cancer Res 65:5761–5768PubMedCrossRefGoogle Scholar
  21. Ohnishi K (2007) PML-RARα inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promy-elocytic leukemia. International Journal of Clinical Oncology 12:313–317PubMedCrossRefGoogle Scholar
  22. Oishi Y, Manabe I, Tobe K et al (2008) SUMOylation of Kruppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-[delta]. Nat Med 14:656–666PubMedCrossRefGoogle Scholar
  23. Oishi Y, Manabe I, Tobe K et al (2005) Krüppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metab 1:27–39PubMedCrossRefGoogle Scholar
  24. Parisi S, Passaro F, Aloia L et al (2008) Klf5 is involved in self-renewal of mouse embryonic stem cells. J Cell Sci 121:2629–2634PubMedCrossRefGoogle Scholar
  25. Parmar KM, Nambudiri V, Dai G et al (2005) Statins Exert Endothelial Atheroprotective Effects via the KLF2 Transcription Factor. J Biol Chem 280:26714–26719PubMedCrossRefGoogle Scholar
  26. Rosenfeld MG, Lunyak VV, Glass CK (2006) Sensors and signals: a coactivator/corepressor/ epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 20:1405–1428PubMedCrossRefGoogle Scholar
  27. Sen-Banerjee S, Mir S, Lin Z et al (2005) Kruppel-Like Factor 2 as a Novel Mediator of Statin Effects in Endothelial Cells. Circulation 112:720–726PubMedCrossRefGoogle Scholar
  28. Shindo T, Manabe I, Fukushima Y et al (2002) Krüppel-like zinc-finger transcription factor KLF5/ BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med 8:856–863PubMedGoogle Scholar
  29. Takahashi K and Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676PubMedCrossRefGoogle Scholar
  30. Tong D, Czerwenka K, Heinze G et al (2006) Expression of KLF5 is a Prognostic Factor for Disease-Free Survival and Overall Survival in Patients with Breast Cancer. Clin Cancer Res 12:2442–2448PubMedCrossRefGoogle Scholar
  31. Voutsadakis I (2007) Peroxisome proliferator-activated receptor γ (PPARγ) and colorectal carcino-genesis. J Cancer Res Clin Oncol 133:917–928PubMedCrossRefGoogle Scholar
  32. Watanabe N, Kurabayashi M, Shimomura Y et al (1999) BTEB2, a Kruppel-like transcription factor, regulates expression of the SMemb/Nonmuscle myosin heavy chain B (SMemb/ NMHC-B) gene. Circ Res 85:182–191PubMedGoogle Scholar
  33. Yagi N, Manabe I, Tottori T et al (2009) A Nanoparticle System Specifically Designed to Deliver siRNA Inhibits Tumor Growth in vivo. Cancer Res in pressGoogle Scholar
  34. Yoshida T, Gan Q, Owens GK (2008) Kruppel-like factor 4, Elk-1, and histone deacetylases cooperatively suppress smooth muscle cell differentiation markers in response to oxidized phospholipids. Am J Physiol Cell Physiol:00288.02008Google Scholar
  35. Zhang X-L, Zhang D, Michel FJ et al (2003) Selective Interactions of Kruppel-like Factor 9/ Basic Transcription Element-binding Protein with Progesterone Receptor Isoforms A and B Determine Transcriptional Activity of Progesterone-responsive Genes in Endometrial Epithelial Cells. J Biol Chem 278:21474–21482PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  • Ichiro Manabe
    • Ryozo Nagai

      There are no affiliations available

      Personalised recommendations